Skip to main content
SpringerLink
Log in

Genetic polymorphism affects MTX discontinuation for RA

  • Epidemiology clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. MTHFR = 5,10-methylenetetrahydrofolate reductase (i.e. a central regulatory enzyme in the folic acid pathway); GAPAID = Genes and Proteins for AutoImmunity Diagnostics.

  2. Patients who discontinued MTX therapy were classed as non-responders, and patients who did not discontinue MTX therapy were classed as responders − regardless of whether it was due to an adverse effect or lack of efficacy.

Reference

  • Uribarri M, et al. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project. Clinical and Experimental Rheumatology : [7 pages], 27 Aug 2015. Available from: URL: http://www.clinexprheumatol.org/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genetic polymorphism affects MTX discontinuation for RA. Reactions Weekly 1572, 10 (2015). https://doi.org/10.1007/s40278-015-1035-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-1035-6

Search

Navigation